AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026

AtaiBeckley Inc. (NASDAQ: ATAI), a clinical-stage biotechnology company developing mental health treatments, announced participation in four major investor conferences in June 2026, including the Jefferies Global Healthcare Conference, Oppenheimer CNS and Neuro-Muscular Summit, HCW Neuro Perspectives Conference, and UBS Virtual CNS Day. The company is advancing its pipeline including BPL-003 for treatment-resistant depression in Phase 3 planning, VLS-01 and EMP-01 in Phase 2 development.

05/27/2026, 6:00 AM • GlobeNewswire

AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder

AtaiBeckley reported expanded Phase 2a trial results for EMP-01 (oral R-MDMA) in social anxiety disorder, demonstrating 49% responder rates and clinically meaningful improvements across multiple symptom measures (LSAS, SPIN, SAFE) with a favorable safety profile and no serious adverse events. The treatment showed a 38% reduction in patient-reported symptoms versus 15% on placebo, with durability observed after just two administrations over 28 days.

04/22/2026, 6:00 AM • GlobeNewswire

AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences

AtaiBeckley Inc. announced that Co-Founder and CEO Dr. Srinivas Rao will participate in the 25th Annual Needham Virtual Healthcare Conference (April 13-16) and the Needham Virtual Psychedelics Forum (April 27). The company's lead candidate BPL-003 (mebufotenin benzoate nasal spray) has received FDA Breakthrough Therapy Designation and is on track to enter Phase 3 studies in Q2 2026 following a successful End-of-Phase 2 meeting with the FDA.

04/14/2026, 6:00 AM • GlobeNewswire

BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation

AtaiBeckley Inc. announced peer-reviewed Phase 2a results for BPL-003 (mebufotenin benzoate nasal spray) in treatment-resistant depression, showing a mean MADRS score reduction of 12.6 points by Day 2 that was sustained over 12 weeks. The drug demonstrated a 54.5% response rate and 63.6% remission rate with good tolerability. The Phase 3 program remains on track for initiation in Q2 2026 following a successful FDA End-of-Phase 2 meeting.

03/17/2026, 6:00 AM • GlobeNewswire

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update

AtaiBeckley announced Q4 2025 financial results with $220.7M in cash runway through early 2029. The company received FDA approval to advance BPL-003 (mebufotenin benzoate nasal spray) into Phase 3 trials for treatment-resistant depression, with initiation planned for Q2 2026. EMP-01 (oral R-MDMA) met primary safety objectives in a Phase 2a social anxiety disorder trial with clinically meaningful efficacy improvements. VLS-01 Phase 2 data is anticipated in H2 2026.

03/06/2026, 7:00 AM • GlobeNewswire

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments

Five psychedelic biotech companies are advancing toward Phase 3 trials for treating depression and anxiety disorders. Helus Pharma reported positive Phase 2a results for SPL026 in major depressive disorder published in Nature Medicine. AtaiBeckley, Definium Therapeutics, GH Research, and LB Pharmaceuticals are all progressing late-stage clinical programs with multiple Phase 3 readouts expected in 2026, signaling the sector's maturation toward regulatory approval.

02/27/2026, 11:44 AM • Benzinga

AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation

AtaiBeckley presented clinical and preclinical data at the 64th Annual ACNP Meeting in Nassau, Bahamas. The company's Phase 2b study of BPL-003 (mebufotenin benzoate) nasal spray for treatment-resistant depression showed significant rapid and sustained antidepressant effects at 8mg and 12mg doses compared to control, with good tolerability. The presentation was selected for the prestigious Hot Topics Session. Additionally, preclinical data on 5-MeO-DMT's pharmacology and potential neuroplasticity effects were presented.

01/16/2026, 7:00 AM • GlobeNewswire

AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference

AtaiBeckley Inc (NASDAQ: ATAI), formed from the merger of atai Life Sciences and Beckley Psytech, announced its 2026 outlook ahead of the J.P. Morgan Healthcare Conference. The company reported positive Phase 2b data for BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression, with Phase 3 trials expected in Q2 2026. Additional milestones include Phase 2 data for VLS-01 (DMT buccal film) in H2 2026 and EMP-01 (oral R-MDMA) for social anxiety disorder in Q1 2026. The company completed its redomiciliation to the United States in December 2025 and was added to the NASDAQ Biotechnology Index.

01/08/2026, 7:00 AM • GlobeNewswire

Why Atai Life Sciences Stock Was So Lively This Week

Atai Life Sciences received FDA Breakthrough Therapy designation for BPL-003, a nasal spray targeting treatment-resistant depression. The company also raised approximately $130 million through a stock offering to advance its clinical programs.

10/17/2025, 8:06 AM • The Motley Fool

atai Life Sciences Announces Pricing of Public Offering of Common Shares

atai Life Sciences plans to raise approximately $130 million through a public offering of 23,725,000 common shares at $5.48 per share, with proceeds intended to advance clinical development of product candidates and support corporate operations.

10/16/2025, 10:31 PM • GlobeNewswire

atai Life Sciences Awarded Grant from the National Institutes of Health

atai Life Sciences received a multi-year, milestone-driven grant from NIDA to develop novel non-hallucinogenic 5-HT2A/2C receptor agonists for treating opioid use disorder, focusing on innovative drug discovery approaches.

09/18/2025, 8:00 AM • GlobeNewswire

Atai Life Sciences Revenue Jumps 163%

Atai Life Sciences reported Q2 2025 financial results with mixed performance, including revenue of $0.72 million, reduced net loss of $27.7 million, and continued progress in mental health treatment drug development, with a strategic combination with Beckley Psytech planned.

08/14/2025, 7:31 AM • The Motley Fool

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

atai Life Sciences and Beckley Psytech reported successful Phase 2b clinical trial results for BPL-003, a potential treatment for treatment-resistant depression, demonstrating rapid and durable antidepressant effects with a single intranasal dose and minimal side effects.

07/01/2025, 6:00 AM • GlobeNewswire